siRNA-loaded PEGylated porous silicon nanoparticles for lung cancer therapy
Source abstract
Abstract
Biocompatible and biodegradable porous silicon nanoparticles (pSiNPs) with tunable pore size have been used as vehicles for drug delivery. Our pSiNPs have a mean size of 110 nm with an average pore size of 26 nm. Approximately 16.3 µg of siRNA can be loaded per mg of pSiNPs followed by polyethylene glycol (PEG) surface coating. siRNA-loaded PEGylated pSiNPs (P-pSiNPs) can be uptaken by A549 cells, and target pyruvate kinase isozyme type M2 (PKM2) mRNA and protein expression were effectively downregulated to 6.3 and 26.8 %, respectively. Cell viability decreased to 37.6 %; meanwhile, cell apoptosis upregulated to 17.3 %. The results prove that the siRNA-loaded pSiNPs coated with PEG can effectively deliver siRNA into cancer cells, and the efficiency is comparable to that of lipofectamine.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · Silicon Nanostructures and Photoluminescence · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (37)
Show source-provided references
1. Alexis F, Pridgen E, Langer R, Farokhzad O (2010) Nanoparticle Technologies for Cancer Therapy. In: Schäfer-Korting M (ed) Drug delivery. Springer, Berlin Heidelberg, pp 55–8610.1007/978-3-642-00477-3_2 ↗
2. Anglin E, Cheng L, Freeman W, Sailor M (2008) Porous silicon in drug delivery devices and materials. Adv Drug Deliv Rev 60:126610.1016/j.addr.2008.03.017 ↗
3. Bayliss SC, Heald R, Fletcher DI, Buckberry LD (1999) The culture of mammalian cells on nanostructured silicon. Adv Mater 11(4):318–32110.1002/(SICI)1521-4095(199903)11:4<318::AID-ADMA318>3.0.CO;2-Z ↗
4. Bimbo LM, Sarparanta M, Santos HA, Airaksinen AJ, Makila E, Laaksonen T, Peltonen L, Lehto V-P, Hirvonen J, Salonen J (2010) Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. ACS Nano 4(6):3023–303210.1021/nn901657w ↗
5. Chen J, Xie J, Jiang Z, Wang B, Wang Y, Hu X (2011) Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene 30(42):4297–430610.1038/onc.2011.137 ↗
6. Choi CHJ, Zuckerman JE, Webster P, Davis ME (2011) Targeting kidney mesangium by nanoparticles of defined size. Proc Natl Acad Sci 108(16):6656–666110.1073/pnas.1103573108 ↗
7. Cioca DP, Aoki Y, Kiyosawa K (2003) RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther 10(2):125–13310.1038/sj.cgt.7700544 ↗
8. Curtis A, Wilkinson C (1997) Topographical control of cells. Biomaterials 18(24):1573–158310.1016/S0142-9612(97)00144-0 ↗
9. Dykxhoorn DM, Lieberman J (2006) Knocking down disease with siRNAs. Cell 126(2):231–23510.1016/j.cell.2006.07.007 ↗
10. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411(6836):494–49810.1038/35078107 ↗
11. Goldberg MS, Sharp PA (2012) Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med 209(2):217–22410.1084/jem.20111487 ↗
12. Gu L, Hall DJ, Qin Z, Anglin E, Joo J, Mooney DJ, Howell SB, Sailor MJ (2013) In vivo time-gated fluorescence imaging with biodegradable luminescent porous silicon nanoparticles. Nat commun 4: doi: 10.1038/ncomms332610.1038/ncomms3326 ↗
13. Hom C, Lu J, Liong M, Luo H, Li Z, Zink JI, Tamanoi F (2010) Mesoporous silica nanoparticles facilitate delivery of sirna to shutdown signaling pathways in mammalian cells. Small 6(11):1185–119010.1002/smll.200901966 ↗
14. Hughes GA (2005) Nanostructure-mediated drug delivery. Nanomed Nanotechnol Biol Med 1(1):22–3010.1016/j.nano.2004.11.009 ↗
15. Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW (2013) PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 155(2):397–40910.1016/j.cell.2013.09.025 ↗
16. Jackson AL, Linsley PS (2004) Noise amidst the silence: off-target effects of siRNAs? Trends Genet 20(11):521–52410.1016/j.tig.2004.08.006 ↗
17. Jackson AL, Linsley PS (2010) Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 9(1):57–6710.1038/nrd3010 ↗
18. Lee Y, Oh W, Dao VA, Hussain SQ, Yi J (2012) Ultrathin oxide passivation layer by rapid thermal oxidation for the silicon heterojunction solar cell applications. Int J Photoenergy10.1155/2012/753456 ↗
19. Li X, Xie QR, Zhang J, Xia W, Gu H (2011a) The packaging of siRNA within the mesoporous structure of silica nanoparticles. Biomaterials 32(35):9546–955610.1016/j.biomaterials.2011.08.068 ↗
20. Li X, Zhang J, Gu H (2011b) Adsorption and desorption behaviors of DNA with magnetic mesoporous silica nanoparticles. Langmuir 27(10):6099–610610.1021/la104653s ↗
21. Lu J, Liong M, Li Z, Zink JI, Tamanoi F (2010) Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small 6(16):1794–180510.1002/smll.201000538 ↗
22. Luo W, Semenza GL (2012) Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol Metab 23(11):560–56610.1016/j.tem.2012.06.010 ↗
23. Masiero M, Nardo G, Indraccolo S, Favaro E (2007) RNA interference: implications for cancer treatment. Mol Aspects Med 28(1):143–16610.1016/j.mam.2006.12.004 ↗
24. McCarroll J, Kavallaris M (2012) Nanoparticle delivery of siRNA as a novel therapeutic for human disease. Aust Biochem 43(3):9–20
25. Na H-K, Kim M-H, Park K, Ryoo S-R, Lee KE, Jeon H, Ryoo R, Hyeon C, Min D-H (2012) Efficient functional delivery of siRNA using mesoporous silica nanoparticles with ultralarge pores. Small 8(11):1752–176110.1002/smll.201200028 ↗
26. Park J-H, Gu L, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ (2009) Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat Mater 8(4):331–33610.1038/nmat2398 ↗
27. Sailor MJ, Wu EC (2009) Photoluminescence-based sensing with porous silicon films, microparticles, and nanoparticles. Adv Funct Mater 19(20):3195–320810.1002/adfm.200900535 ↗
28. Secret E, Smith K, Dubljevic V, Moore E, Macardle P, Delalat B, Rogers M-L, Johns TG, Durand J-O, Cunin F, Voelcker NH (2012) Antibody-functionalized porous silicon nanoparticles for vectorization of hydrophobic drugs. Adv Healthc Materi n/a-n/a10.1002/adhm.201200335 ↗
29. Shim MS, Kwon YJ (2010) Efficient and targeted delivery of siRNA in vivo. FEBS J 277(23):4814–482710.1111/j.1742-4658.2010.07904.x ↗
30. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, Christofk HR, Wagner G, Rabinowitz JD, Asara JM (2010) Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329(5998):1492–149910.1126/science.1188015 ↗
31. Wan Y, Apostolou S, Dronov R, Kuss B, Voelcker NH (2014) Cancer-targeting siRNA delivery from porous silicon nanoparticles. Nanomedicine (0), 1–1310.2217/nnm.14.12 ↗
32. Wang Z, Jeon HY, Rigo F, Bennett CF, Krainer AR (2012) Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides. Open biol 2(10):12013310.1098/rsob.120133 ↗
33. Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8(2):129–13810.1038/nrd2742 ↗
34. Wu EC, Andrew JS, Buyanin A, Kinsella JM, Sailor MJ (2011) Suitability of porous silicon microparticles for the long-term delivery of redox-active therapeutics. Chem Commun 47(20):5699–570110.1039/c1cc10993f ↗
35. Xia T, Kovochich M, Liong M, Meng H, Kabehie S, George S, Zink JI, Nel AE (2009) Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of sirna and DNA constructs. ACS Nano 3(10):3273–328610.1021/nn900918w ↗
36. Xia B, Zhang W, Bao W, Dong C, Zhang J, Shi J (2012) Photoluminescence enhancement of porous silicon particles by microwave-assisted activation. physica status solidi (a) 209(11):2247–225010.1002/pssa.201228309 ↗
37. Zhang Y, Pan H, Zhang P, Gao N, Lin Y, Luo Z, Li P, Wang C, Liu L, Pang D (2013) Functionalized quantum dots induce proinflammatory responses in vitro: the role of terminal functional group-associated endocytic pathways. Nanoscale 5(13):5919–592910.1039/c3nr01653f ↗